As Matt Lehman stated today,Prima is in a relatively good...

As Matt Lehman stated today,Prima is in a relatively good position to negotiate favorable terms of any future collaboration deals with big pharma.Prima Biomed is unencumbered financially, has strong IP and excellent technology.However,there is no doubt that Prima will need to find significant funds to commercialize CVac and other than to go it alone (see Dendreon)or be acquired by a predator, a big pharma partner may be the best option for the company and its shareholders?
See below a recent example of such a deal. Endocyte are in phase 2/3 trials of Vintafolide, a 'targeted therapy for the treatment of ovarian cancer'. Vintafolide is not a competitor to CVac as it is designed to enable the treatment of patients with highly active drugs at greater doses more frequently.Here's the rub:

Merck & Co Inc and Endocyte Inc.announced that they have entered into an agreement to develop and commercialize Endocyte's investigational therapeutic candidate vintafolide (EC145). Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120 million upfront payment and is eligible for payments of up to $880 million based on the achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications. In addition, if vintafolide receives regulatory approval, Endocyte will receive an equal share of the profit in the United States (U.S.) as well as a double digit percentage royalty on sales of the product in the rest of the world. Endocyte has retained the right to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of world. Endocyte will be responsible for the majority of funding and completion of the PROCEED trial (phase 3). Merck will be responsible for all other development activities and costs and have all decision rights for vintafolide. Endocyte remains responsible for the development, manufacture and commercialization worldwide of etarfolatide, a non-invasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.

Read the last sentence again and refer back to Matt Lehman's reference today to his presentation regarding Prima's strategy to develop a 'companion screening tool'. This I believe will be a game changer for Prima going forward to predict whether the CVac willeffectively reach the site of other cancer types.

I would be comfortable with a similar collaboration deal to that above. Oh, by the way, Endocyte's market cap doubled overnight upon the deal with Merck being announced in April this year.